Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1701 in Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT04282070Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Mar 2020
- Primary completion
- Apr 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of retlirafusp alfa in nasopharyngeal carcinoma (NPC) (4 arms), sponsored by Hengrui. Primary endpoint: Toxicity up to 2 years. Status: unknown.
02
Drugs
retlirafusp alfa
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04282070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04282070.